Close Menu

More articles about Clinical Proteomics

Thermo Fisher Scientific said this week that it has acquired protein biomarker firm Intrinsic Bioprobes, adding to its clinical proteomics portfolio.

The partners will co-develop mass spectrometry-based tests to predict patient response to therapies such as tamoxifen.

According to a document filed with the SEC, Biodesix has raised half of its goal of $20 million. Funds will be used to further commercialize its VeriStrat test.

The collaboration will combine Metamark's multiplex protein detection platform with image analysis technology that the firm will jointly develop with Definiens.

The NIH wants to fuel development of new proteomics technologies and glycomics tools through its SBIR/STTR program.

The findings suggest that guidelines for chronic kidney disease testing, which have come under increased scrutiny in recent years, could benefit from including albumin and cystatin C levels in definitions of the disease.

New Products: Apr 22, 2011

Premium

Intrinsic Bioprobes, GE Healthcare

The Center for Personalized Cancer Therapy is a joint program with the Dana-Farber/Harvard Cancer Center.

Genentech is proposing to conduct a randomized, controlled confirmatory trial that "would include a biomarker component to identify patients who may be more likely to derive a more substantial benefit from Avastin." Such a strategy would align with FDA's personalized medicine focus, the company points out.

Attention to assay reproducibility and selection of appropriate intended use populations will be key to the success of proteomics-based tests, FDA staff fellow Joshua Levin suggested at a talk this week discussing the agency's review of two mock submissions for protein IVDMIAs.

According to the patent, the company identified the proteins serum amyloid A and S-sulfonated transthyretin as biomarkers for myocardial infarction and developed a three-marker panel consisting of SAA, SS-TTR, and known MI biomarker myoglobin.

With diagnostic development shifting from single-marker to multi-marker tests, multiple-reaction monitoring mass spectrometry has emerged as a potentially valuable clinical tool. Further improvements in the platform's cost and variability are needed, however, to make it competitive with immunoassays.

The collaboration aims to turn IBI's mass-spec immunoassay technology from a tool it has offered exclusively on a contract-research basis into a turnkey product available to clinical research laboratories around the world.

The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.

Pages

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.